NCT05064735: A reported trial by Novo Nordisk A/S
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05064735 |
|---|---|
| Title | Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2021 |
| Completion date | July 24, 2023 |
| Required reporting date | July 23, 2024, midnight |
| Actual reporting date | July 20, 2024 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |